Botanix Pharmaceuticals Reports 45% Increase in Sofdra Net Revenue in Q4 FY26 with Record Monthly Shipments

Record Sofdra Prescription Shipments Drive Accelerated Growth in Q4 FY26

Botanix Pharmaceuticals reported accelerating commercial traction for Sofdra, its FDA-approved topical gel for hyperhidrosis. Total prescriptions shipped in Q4 FY26 reached 33,358 units, a 25% increase from 26,684 units in Q3 FY26. June 2026 set a record with 12,895 prescriptions shipped, highlighting strong market adoption. This growth follows seasonal trends, with slower expansion in early 2026 during the northern hemisphere winter and accelerated growth from March onward.

The prescription surge is notable amid the company’s strategic sales force optimisation. Botanix credits strong performance to increased market awareness of Sofdra’s clinical benefits and deeper penetration in dermatology practices. The company’s commercial infrastructure supports rapid scaling, and management is confident in sustaining this momentum. The record June shipments establish a benchmark for investors regarding Sofdra’s US dermatology market potential.

Net Revenue Increases 45% with Improved Gross-to-Net Yield of 22%

Sofdra’s net revenue rose 45% to $10.1 million in Q4 FY26 from $6.9 million in Q3 FY26, outpacing prescription growth. This reflects an improved gross-to-net (GTN) yield of 22% in Q4 FY26, up from 18% in Q3 FY26. The company attributes this to the normalisation of US healthcare insurance deductibles after their annual reset, affecting about half of privately insured Americans under 65. Patients initially face higher out-of-pocket costs early in the year, reducing net revenue, but as deductibles are met, revenue per prescription improves.

Gross sales increased 23% quarter-on-quarter to $46.7 million in Q4 FY26 from $38.0 million in Q3 FY26. Management expects GTN yield to continue rising into Q1 FY27, suggesting further revenue growth potential even if prescription volumes stabilize. This highlights the impact of US healthcare payment dynamics on revenue and indicates Sofdra is gaining insurance formulary coverage and patient acceptance beyond cash-pay segments.

Operating Cash Outflow Drops 54% Due to Manufacturing and Cost Controls

Botanix’s operating cash outflow improved significantly, decreasing 54% to $10.6 million in Q4 FY26 from $23.3 million in Q3 FY26. This was driven by increased sales receipts and the strategic deferral of a $9.7 million API purchase originally scheduled for April 2026. The renegotiated API supply agreement allowed the company to preserve cash while maintaining adequate inventory to meet Sofdra demand.

Manufacturing costs fell sharply to $1.2 million in Q4 FY26 from $11.0 million in Q3 FY26, mainly due to the deferred API purchase. Operating expenses declined 10% to $11.5 million, reflecting disciplined cost management. This improvement in cash burn is critical for investors assessing the company’s path to cash flow breakeven, showing Sofdra revenue growth beginning to offset operating costs. The combination of higher revenue and deferred capital expenditure enhances financial flexibility.

Cash Reserves Strengthen to $36.6 Million Following Capital Raise

As of 30 June 2026, Botanix held $36.6 million in cash, up $14.5 million from $22.1 million at the end of Q3 FY26. This increase includes $30.1 million (pre-costs) from the remaining tranche of a $45 million capital raise. The raise provides a vital cash runway to support Sofdra’s commercial expansion, supply chain development, and strategic initiatives.

The stronger cash position gives management greater flexibility to pursue operational improvements and potential licensing or acquisition deals. Botanix is actively engaging with inbound interest in such partnerships. The cash buffer also helps absorb timing mismatches between inventory investment and revenue recognition. With $36.6 million in cash and a $10.6 million quarterly operating outflow, the company’s runway extends over multiple quarters, allowing time to achieve cash flow positive operations from product sales.

Sales Force Restructuring to Cut Operating Costs by 12% Starting July 2026

Botanix is implementing a sales force optimisation to boost efficiency and ROI. Analysis showed that 90% of Sofdra prescriptions came from 39 of 50 sales territories. The company will eliminate 11 underperforming territories by reallocating key physician targets to the 39 high-performing territories, maintaining 94% physician coverage while reducing headcount. This restructuring begins 31 July 2026.

The reduction is expected to lower operating costs by roughly 12%, a significant expense cut. This reflects management’s focus on resource allocation and profitability, recognising that growth-stage commercialisation does not require proportional cost increases. Concentrating efforts on productive channels aims to sustain prescription growth while reducing fixed costs. For investors, this demonstrates commitment to balancing growth with operating leverage, critical for Sofdra’s path to profitability.

Piramal Onboarding as Alternative API Supplier to Boost Supply Chain Resilience

Botanix is onboarding Piramal as a second API supplier for Sofdra, with completion expected in 2028. This dual-supplier strategy enhances supply chain resilience, manufacturing flexibility, and reduces long-term costs. The company renegotiated its existing API supply agreement to defer a $9.7 million purchase to future periods.

Relying on a single API source poses operational risks; adding Piramal mitigates this risk and supports growing product demand. The new supplier is expected to provide alternative manufacturing capacity and potentially better commercial terms as production scales. This aligns with Botanix’s strategy to improve gross margins through supply chain initiatives. By 2028, with increased Sofdra volumes, alternative manufacturing capacity will be crucial for sustainable profitability.

Extended European and US Patent Protections Through 2040

In July 2026, Botanix announced key intellectual property achievements: an Intention to Grant for a European patent on the Sofdra applicator and a Notice of Allowance for a US patent on the Sofdra drug substance. These extend Sofdra’s patent protections through 2040, securing long-term exclusivity and regulatory safeguards.

This extended patent estate is vital for Botanix’s valuation and commercial outlook, providing a 14-year exclusivity window from 2026 that prevents generic or biosimilar competitors from copying Sofdra’s formulation or applicator. These developments complement existing patents covering various aspects of the product platform, reducing risks of rapid generic competition. For investors, this strengthens confidence in Sofdra’s market position.

Strategic Emphasis on Licensing and Acquisition Opportunities

Botanix’s latest update highlights a strategic focus on evaluating acquisition and licensing opportunities to leverage its commercial infrastructure. Management noted strong inbound interest in partnerships, reflecting the value of Botanix’s sales force, patient services, and proprietary fulfilment platform.

With excess capacity in its commercial infrastructure, Botanix aims to support additional dermatology products without proportional cost increases. Acquiring or licensing complementary products could improve operating leverage and accelerate profitability. The scalable Botanix Fulfilment Platform differentiates the company from single-product firms and suggests multiple pathways to value creation beyond Sofdra’s standalone success.

Appointment of COO Signals Operational Focus and Leadership Strengthening

Paul Seaback was promoted from Chief Technical Officer to Chief Operating Officer. With over 30 years in biopharmaceuticals, he will oversee daily operations, strategic initiatives, and support growth and efficiency improvements. This leadership change underscores management’s commitment to operational excellence during Sofdra’s commercial phase.

Seaback’s technical background positions him well to manage manufacturing, supply chain, and the Piramal onboarding process. For investors, his appointment signals a focus on operational efficiency and scalable execution rather than solely rapid commercial expansion.

FY26 Achievements and Forward-Looking Strategic Priorities for Botanix

Management described FY26 as a pivotal year marked by Sofdra’s commercial launch and growth, operational execution, capital efficiency gains, and strategic progress. Key priorities include continued Sofdra growth, strategic acquisitions leveraging commercial infrastructure, engagement with licensing interest, IP strengthening, Piramal onboarding, cash flow improvement, sales force optimisation, and validating the Botanix Fulfilment Platform for additional products.

This comprehensive strategy reflects a multifaceted approach to value creation and risk management. Beyond Sofdra’s growth, Botanix is building optionality through supply chain resilience, IP protection, and potential M&A or licensing deals. The focus on cash flow and cost discipline acknowledges that scaling sales does not guarantee profitability without efficient management. For investors, these initiatives indicate active management of the company’s trajectory toward sustainable profitability and enhanced enterprise value.